Anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) represents a paradigm for precision medicine with significant clinical benefit in terms of overall survival (OS) and quality of life from the increasing utilization of tyrosine kinase inhibitors (TKIs) during the past decade.1 This evidence concerns the gene ALK and non-small cell lung carcinoma.